ArticleDrug delivery and translational research2026
Chitosan-TPP modification of SNEDDS enhances mucin interaction, apparent epithelial transport, and oral exposure of ezetimibe.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poor aqueous solubility limits the oral absorption of ezetimibe, and conventional self-nanoemulsifying drug delivery systems (SNEDDS) primarily address the solubilization barrier. In this study, ezetimibe-loaded SNEDDS were associated with a chitosan-tripolyphosphate (TPP) ionic network to generate chitosan-TPP-modified SNEDDS colloids (CS-SNEDDS) with additional mucin-interactive characteristics. The resulting CS-SNEDDS had a mean particle size of approximately 142 nm and a positive zeta potential, while retaining the apparent solubilization and rapid dispersion properties of the SNEDDS component. Compared with conventional SNEDDS, CS-SNEDDS showed markedly greater mucin association and increased apparent apical-to-basolateral transport across Caco-2 monolayers. Following oral administration to rats, CS-SNEDDS produced an AUC₀-₂₄h of 4715.62 ± 854.07 ng·h/mL, compared with 3647.39 ± 753.54 ng·h/mL for SNEDDS and 2176.84 ± 426.58 ng·h/mL for crystalline ezetimibe. The AUC₀-₂₄h of CS-SNEDDS was significantly higher than that of SNEDDS, whereas no significant difference in C
Indexed as
Identifiers
42749906What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.